By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced the extension of a deal with Merck KGaA for the use of its MGMT assay in Merck's brain cancer drug clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.